Noradrenalina Generis (Noradrenaline Tartrate)

Noradrenaline Tartrate, the active ingredient in Noradrenalina Generis, is a sympathomimetic vasopressor presented as an injectable solution for intravenous administration. It is employed in critical care to raise blood pressure and improve cardiac output in patients experiencing acute hypotension, septic shock, cardiogenic shock, or cardiac arrest. All batches meet EU pharmacopoeial standards and are manufactured under GMP conditions.

GNH USA supplies Noradrenalina Generis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Noradrenalina Generis, a vasopressor acting on the adrenergic system, is indicated for several acute cardiovascular emergencies.

- Acute hypotension: restores systemic vascular resistance to maintain adequate perfusion pressure. - Septic shock: supports blood pressure when fluid resuscitation alone is insufficient. - Cardiogenic shock: enhances cardiac output by increasing contractility and heart rate. - Cardiac arrest: provides immediate pressor support during advanced life‑saving measures.

Noradrenalina Generis may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: transient, often related to rapid blood pressure changes. - Tachycardia: increased heart rate due to beta‑1 stimulation. - Arrhythmia: premature beats or mild rhythm disturbances. - Hypertension: excessive rise in blood pressure if dose is too high. - Nausea: gastrointestinal discomfort during infusion. - Anxiety: feelings of nervousness or restlessness.

Serious or Rare Side Effects: - Myocardial ischemia: reduced coronary perfusion from high afterload. - Severe arrhythmias: ventricular tachycardia or fibrillation. - Tissue necrosis: extravasation at the infusion site. - Pulmonary edema: fluid accumulation due to increased afterload. - Extreme hypertension: risk of intracranial hemorrhage. - Cardiac arrest: paradoxical failure despite pressor therapy.

Use of Noradrenalina Generis requires careful clinical monitoring and adherence to safety guidelines.

- Cardiovascular monitoring: continuous blood pressure and heart‑rate observation is essential. - Titration: infusion rate should be adjusted to achieve target hemodynamics. - Contraindications: avoid in patients with uncorrected pheochromocytoma or severe peripheral vascular disease. - Drug interactions: monitor closely when combined with MAO inhibitors, tricyclic antidepressants, or ergot alkaloids. - Pregnancy and lactation: only if potential benefit justifies potential risk; data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Noradrenalina Generis can interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Beta‑blockers: may blunt desired chronotropic effects. - Tricyclic antidepressants: additive vasoconstriction and hypertension.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may enhance hypotensive episodes after dose reduction. - Diuretics: synergistic blood‑pressure lowering effect. - Other vasopressors: cumulative pressor effect can cause severe hypertension. - Anesthetic agents: altered hemodynamic response during surgery. - Calcium channel blockers: may affect vascular tone and heart rate.